Skip to main content

Table 1 Basic characteristics of HIV positive subjects

From: Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression

Characteristics ZOL(−) (N = 38) ZOL(+) (N = 36) P value
Age, year 41.2 ± 6.8 40.8 ± 5.6 0.331
Sex, male (%) 31 (81.6) 30 (83.3) 0.324
Race    0.520
 White 13 (34.2) 12 (33.3)  
 Black 25 (65.8) 24 (66.7)  
History of smoking    0.421
 Yes 31 (81.6) 31 (86.1)  
 No 7 (18.4) 5 (13.9)  
Current smoking    0.699
 Yes 29 (76.3) 30 (83.3)  
 No 9 (23.7) 6 (16.7)  
Cigarettes smoked per day (in patients with history of smoking) 3 (7.9) 3 (8.3) 0.383
Years of cigarette smoking (in patients with history of smoking) 3 (7.9) 4 (11.1 + G14:N14) 0.349
History of bone fracture    0.636
 Yes 8 (21.1) 5 (13.9)  
 No 30 (78.9) 31 (86.1)  
HIV RNA, log10 copies/mL (SD) 4.1 ± 0.8 3.7 ± 0.7 0.536
CD4 count, cells/uL (SD) 159.7 ± 37.7 153.3 ± 44.9 0.498
Serum calcium, mg/dL(SD) 9.8 ± 3.8 9.7 ± 2.6 0.568
Serum vitamin D, ng/mL(SD) 24.9 ± 6.1 24.3 ± 5.7 0.430